194 related articles for article (PubMed ID: 37301119)
1. All-trans-retinoic acid inhibits hepatocellular carcinoma progression by targeting myeloid-derived suppressor cells and inhibiting angiogenesis.
Li X; Luo X; Chen S; Chen J; Deng X; Zhong J; Wu H; Huang X; Wang C
Int Immunopharmacol; 2023 Aug; 121():110413. PubMed ID: 37301119
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of myeloid-derived suppressive cell function with all-trans retinoic acid enhanced anti-PD-L1 efficacy in cervical cancer.
Liang Y; Wang W; Zhu X; Yu M; Zhou C
Sci Rep; 2022 Jun; 12(1):9619. PubMed ID: 35688951
[TBL] [Abstract][Full Text] [Related]
3. Targeting the crosstalk between cytokine-induced killer cells and myeloid-derived suppressor cells in hepatocellular carcinoma.
Yu SJ; Ma C; Heinrich B; Brown ZJ; Sandhu M; Zhang Q; Fu Q; Agdashian D; Rosato U; Korangy F; Greten TF
J Hepatol; 2019 Mar; 70(3):449-457. PubMed ID: 30414862
[TBL] [Abstract][Full Text] [Related]
4. All-trans-retinoic acid restores CD4+ T cell response after sepsis by inhibiting the expansion and activation of myeloid-derived suppressor cells.
Liu T; Yang F; Xie J; Chen J; Gao W; Bai X; Li Z
Mol Immunol; 2021 Aug; 136():8-15. PubMed ID: 34051632
[TBL] [Abstract][Full Text] [Related]
5. Targeting myeloid-derived suppressor cells using all-trans retinoic acid in melanoma patients treated with Ipilimumab.
Tobin RP; Jordan KR; Robinson WA; Davis D; Borges VF; Gonzalez R; Lewis KD; McCarter MD
Int Immunopharmacol; 2018 Oct; 63():282-291. PubMed ID: 30121453
[TBL] [Abstract][Full Text] [Related]
6. Identification and validation of Birc5 as a novel activated cell cycle program biomarker associated with infiltration of immunosuppressive myeloid-derived suppressor cells in hepatocellular carcinoma.
Liu Y; Chen X; Luo W; Zhao Y; Nashan B; Huang L; Yuan X
Cancer Med; 2023 Aug; 12(15):16370-16385. PubMed ID: 37326143
[TBL] [Abstract][Full Text] [Related]
7. Blockade of Myeloid-Derived Suppressor Cell Expansion with All-
Bauer R; Udonta F; Wroblewski M; Ben-Batalla I; Santos IM; Taverna F; Kuhlencord M; Gensch V; Päsler S; Vinckier S; Brandner JM; Pantel K; Bokemeyer C; Vogl T; Roth J; Carmeliet P; Loges S
Cancer Res; 2018 Jun; 78(12):3220-3232. PubMed ID: 29674477
[TBL] [Abstract][Full Text] [Related]
8. Hepatic carcinoma-associated fibroblasts enhance immune suppression by facilitating the generation of myeloid-derived suppressor cells.
Deng Y; Cheng J; Fu B; Liu W; Chen G; Zhang Q; Yang Y
Oncogene; 2017 Feb; 36(8):1090-1101. PubMed ID: 27593937
[TBL] [Abstract][Full Text] [Related]
9. Myeloid derived suppressor cells in peripheral blood can be a prognostic factor in canine transitional cell carcinoma.
Yokota S; Yonezawa T; Momoi Y; Maeda S
Vet Immunol Immunopathol; 2024 Mar; 269():110716. PubMed ID: 38308864
[TBL] [Abstract][Full Text] [Related]
10. Hepatoma-intrinsic CCRK inhibition diminishes myeloid-derived suppressor cell immunosuppression and enhances immune-checkpoint blockade efficacy.
Zhou J; Liu M; Sun H; Feng Y; Xu L; Chan AWH; Tong JH; Wong J; Chong CCN; Lai PBS; Wang HK; Tsang SW; Goodwin T; Liu R; Huang L; Chen Z; Sung JJ; Chow KL; To KF; Cheng AS
Gut; 2018 May; 67(5):931-944. PubMed ID: 28939663
[TBL] [Abstract][Full Text] [Related]
11. IL-37 dampens immunosuppressive functions of MDSCs via metabolic reprogramming in the tumor microenvironment.
Mei Y; Zhu Y; Yong KSM; Hanafi ZB; Gong H; Liu Y; Teo HY; Hussain M; Song Y; Chen Q; Liu H
Cell Rep; 2024 Mar; 43(3):113835. PubMed ID: 38412100
[TBL] [Abstract][Full Text] [Related]
12. Macrophages are more potent immune suppressors ex vivo than immature myeloid-derived suppressor cells induced by metastatic murine mammary carcinomas.
Hamilton MJ; Bosiljcic M; Lepard NE; Halvorsen EC; Ho VW; Banáth JP; Krystal G; Bennewith KL
J Immunol; 2014 Jan; 192(1):512-22. PubMed ID: 24285836
[TBL] [Abstract][Full Text] [Related]
13. The restoration of myeloid-derived suppressor cells as functional antigen-presenting cells by NKT cell help and all-trans-retinoic acid treatment.
Lee JM; Seo JH; Kim YJ; Kim YS; Ko HJ; Kang CY
Int J Cancer; 2012 Aug; 131(3):741-51. PubMed ID: 21898392
[TBL] [Abstract][Full Text] [Related]
14. Folate Receptor Beta Designates Immunosuppressive Tumor-Associated Myeloid Cells That Can Be Reprogrammed with Folate-Targeted Drugs.
Cresswell GM; Wang B; Kischuk EM; Broman MM; Alfar RA; Vickman RE; Dimitrov DS; Kularatne SA; Sundaram CP; Singhal S; Eruslanov EB; Crist SA; Elzey BD; Ratliff TL; Low PS
Cancer Res; 2021 Feb; 81(3):671-684. PubMed ID: 33203700
[TBL] [Abstract][Full Text] [Related]
15. The New Era of Cancer Immunotherapy: Targeting Myeloid-Derived Suppressor Cells to Overcome Immune Evasion.
De Cicco P; Ercolano G; Ianaro A
Front Immunol; 2020; 11():1680. PubMed ID: 32849585
[TBL] [Abstract][Full Text] [Related]
16. Targeting of myeloid-derived suppressor cells by all-trans retinoic acid as host-directed therapy for human tuberculosis.
Leukes VN; Dorhoi A; Malherbe ST; Maasdorp E; Khoury J; McAnda S; Walzl G; du Plessis N
Cell Immunol; 2021 Jun; 364():104359. PubMed ID: 33865151
[TBL] [Abstract][Full Text] [Related]
17. Cyclophosphamide-induced myeloid-derived suppressor cell population is immunosuppressive but not identical to myeloid-derived suppressor cells induced by growing TC-1 tumors.
Mikyšková R; Indrová M; Polláková V; Bieblová J; Símová J; Reiniš M
J Immunother; 2012 Jun; 35(5):374-84. PubMed ID: 22576342
[TBL] [Abstract][Full Text] [Related]
18. Targeting myeloid-derived suppressor cells in the treatment of hepatocellular carcinoma: current state and future perspectives.
Lu LC; Chang CJ; Hsu CH
J Hepatocell Carcinoma; 2019; 6():71-84. PubMed ID: 31123667
[TBL] [Abstract][Full Text] [Related]
19. Myeloid-Derived Suppressor Cells in the Tumor Microenvironment.
Dysthe M; Parihar R
Adv Exp Med Biol; 2020; 1224():117-140. PubMed ID: 32036608
[TBL] [Abstract][Full Text] [Related]
20. Novel role of microphthalmia-associated transcription factor in modulating the differentiation and immunosuppressive functions of myeloid-derived suppressor cells.
Lee A; Park H; Lim S; Lim J; Koh J; Jeon YK; Yang Y; Lee MS; Lim JS
J Immunother Cancer; 2023 Jan; 11(1):. PubMed ID: 36627143
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]